4//SEC Filing
Adda Nathalie 4
Accession 0001062993-22-006708
CIK 0001177648other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 6:02 PM ET
Size
15.1 KB
Accession
0001062993-22-006708
Insider Transaction Report
Form 4
Adda Nathalie
Sr. VP & Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2022-03-01$43.46/sh+24,339$1,057,773→ 59,321 total - Sale
Common Stock
2022-03-01$70.26/sh−24,239$1,703,032→ 35,082 total - Sale
Common Stock
2022-03-01$71.06/sh−100$7,106→ 34,982 total - Exercise/Conversion
Common Stock
2022-03-02$43.46/sh+12,481$542,424→ 47,463 total - Sale
Common Stock
2022-03-02$70.07/sh−12,481$874,544→ 34,982 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-03-01−24,339→ 12,481 totalExercise: $43.46Exp: 2025-06-29→ Common Stock (24,339 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2022-03-02−12,481→ 0 totalExercise: $43.46Exp: 2025-06-29→ Common Stock (12,481 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.97, inclusive.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.28, inclusive.
- [F4]100% of the shares subject to the option are fully vested and exercisable.
Issuer
ENANTA PHARMACEUTICALS INC
CIK 0001177648
Entity typeother
Related Parties
1- filerCIK 0001646976
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 6:02 PM ET
- Size
- 15.1 KB